USPTO serial 79428150
LEUCOSELECT
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- LINDEMYER, ANKHI MUKHERJEA
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
Need help with LEUCOSELECT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Active chemical ingredients for the production of pharmaceuticals, veterinary products, dietary supplements and dietetic preparations for human and animal use; chemical additives for the production of pharmaceuticals, veterinary products, dietary supplements and dietetic preparations for human and animal use; chemical substances for use in the manufacture of food ingredients for human and animal use; plant extracts, other than essential oils, for use in the manufacture of pharmaceuticals and dietary supplements; plant extracts, other than essential oils, for use in the manufacture of cosmetics | ACTIVE | — |
| 003 | Herbal extracts, other than essential oils, for cosmetic purposes; cosmetic products | ACTIVE | — |
| 005 | Pharmaceutical preparations for the treatment of cardiovascular system diseases, gastroenteric system diseases, respiratory system diseases, immune and endocrine system diseases, central nervous system diseases, chronic inflammatory diseases, skin diseases, urinary tract diseases, musculoskeletal disorders, metabolic diseases, ocular diseases, peripheral nervous disorders, ageing disorders, liver diseases and chronic fatigue syndrome; pharmaceutical preparations and substances for the treatment of cardiovascular system diseases, gastroenteric system diseases, respiratory system diseases, immune and endocrine system diseases, central nervous system diseases, chronic inflammatory diseases, skin diseases, urinary tract diseases, musculoskeletal disorders, metabolic diseases, ocular diseases, peripheral nervous disorders, ageing disorders, liver diseases and chronic fatigue syndrome; dietary supplements and dietetic preparations adapted for medical purposes for the treatment of cardiovascular system diseases, gastroenteric system diseases, respiratory system diseases, immune and endocrine system diseases, central nervous system diseases, chronic inflammatory diseases, skin diseases, urinary tract diseases, musculoskeletal disorders, metabolic diseases, ocular diseases, peripheral nervous disorders, ageing disorders, liver diseases and chronic fatigue syndrome for human use; plant and herb extracts, other than essential oils, for medicinal and pharmaceutical use, and used as an integral component of dietary supplements for humans | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 18, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 18, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 12, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 21, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 21, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 21, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 21, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 21, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 6, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| May 12, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 11, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 11, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 1, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 15, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 14, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 17, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 16, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 16, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 18, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 18, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 17, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |